Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Exec Compensation
confidence 95%
filed 2026-06-22
EX-99.1
This exhibit is a supplemental letter to Tower's proxy statement seeking shareholder approval of an amended and restated compensation policy for directors and executive officers under Israeli law. The letter details proposed changes to compensation arrangements, including increases to CEO maximum annual bonus (175% to 225% of salary), CEO equity award limits (10x to 13x salary), and other executive officer compensation caps. These are material compensatory arrangements requiring shareholder approval under Section 5.02(e) of the 8-K taxonomy and Israeli corporate governance law.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
RedHill Biopharma entered into a Securities Purchase Agreement on June 18, 2026, for a private placement of 8,571,429 ADSs (each representing 10,000 ordinary shares), Series A-1 and Series A-2 warrants, and pre-funded warrants at a combined purchase price of $0.70 per ADS and accompanying warrants. The offering is expected to generate approximately $6 million in gross proceeds, with potential additional proceeds of $13.4 million if warrants are fully exercised. This is a classic dilutive equity issuance to an accredited investor under Section 4(a)(2) and Regulation D, materially affecting shareholder ownership and voting rights.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
RedHill Biopharma announced the closing of a private placement of 8,571,429 ADSs at $0.70 per ADS with accompanying warrants, generating $6 million upfront with up to $13.4 million in potential proceeds from warrant exercises. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, representing a dilutive capital raise typical of small- and mid-cap biopharmaceutical companies. The company explicitly notes the securities "have not been registered under the Securities Act" and references a registration rights agreement for future resale registration, confirming the private placement structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-22
Item 8.01
The filing discloses the consummation of a merger combination between the registrant and RTB Digital, Inc. on May 12, 2026, with completion of share issuance obligations under the merger agreement as of the filing date. This represents a material acquisition/change of control event, even though disclosed under Item 8.01 rather than the typical Item 1.01 or 2.01.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-22
Item 7.01
RTB Digital announced the launch of a real-time, AI/DeFi payment platform for professional publishers, enabling instant USDC settlement of ad revenue through Coinbase integration and a proprietary Media Liquidity Pool. This material product launch and strategic operational milestone affects the company's core business model and competitive positioning in the media technology industry.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-22
Item 8.01
Baker Hughes discloses an update on its pending acquisition of Chart Industries, specifically that the parties are in discussions with the European Commission regarding regulatory commitments to obtain Phase I clearance. The filing confirms the Merger Agreement entered into on July 28, 2025, and provides a status update on the regulatory approval process with an expected closing in July 2026. This is a material acquisition activity disclosure under Item 8.01 (Other Events), as it concerns the progress and regulatory status of a significant M&A transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Codexis's 2026 Annual Meeting held on June 17, 2026. The filing reports final voting tallies on three proposals: election of three directors (Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi), ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation. The disclosure includes vote counts (For, Against, Withheld, Abstain, Broker Non-Votes) for each proposal, certified by the Inspector of Elections.
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-06-22
EX-99
Exhibit 99.2 discloses UMC's disposal of 3,500,832 common shares of Novatek Microelectronics Corporation through conversion of zero-coupon exchangeable bonds due 2026, generating a gain of approximately NTD 1.4 billion to retained earnings. This is a material financial transaction (41.71% of total assets, 57.09% of shareholder equity) involving a significant securities disposition, but does not fit the specific categories of debt issuance, dividend distribution, or M&A activity. Exhibit 99.1 is a routine clarification of market rumors with no substantive disclosure.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-22
EX-99.1
PLDT announced that VITRO Inc. (a wholly-owned subsidiary of ePLDT, itself a wholly-owned subsidiary of PLDT) has submitted a registration statement for a proposed REIT IPO. The disclosure describes a planned secondary offering of up to 1.9 billion shares expected to raise gross proceeds of up to ₱24.2 billion, representing approximately 48.95% of VITRO REIT's post-offering capital. This constitutes a material capital-raising and restructuring activity involving the creation of a new publicly-traded entity within the PLDT Group's digital infrastructure portfolio, which would materially affect investor assessment of PLDT's capital structure and strategic positioning.
View raw filing on EDGAR →
6-K
Governance Other
confidence 75%
filed 2026-06-22
EX-99
The exhibit discloses two governance matters: (1) RBI approval for extension of Mr. Keki Mistry's tenure as interim Part-time Chairman for 3 months until September 18, 2026, and (2) Board approval to convene the 32nd AGM on August 5, 2026, with a proposed dividend of Rs. 13 per share subject to shareholder approval. While the dividend announcement is material, the primary focus is the interim chairman extension and AGM scheduling, which are governance events. The chairman tenure extension is material to investors as it addresses leadership continuity during an interim period, though it does not fit the specific `exec_appointment` or `exec_departure` categories since Mistry is already serving and this is merely an extension of his interim role.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-22
Item 8.01
The filing discloses an update on a material acquisition: Chart Industries is being acquired by Baker Hughes pursuant to a Merger Agreement entered into on July 28, 2025. The current disclosure reports progress toward closing, including ongoing regulatory discussions with the European Commission regarding Phase I review commitments. The expected closing date of July 2026 and the materiality of the transaction (a complete change of control) clearly fall within the ma_activity category.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-22
Birkenstock closed a €900 million offering of 4.500% Senior Notes due 2033 on June 19, 2026. The filing discloses the terms of the new debt issuance, including interest rate, maturity date, ranking, covenants, and redemption provisions. The proceeds will be used to redeem existing notes, fund share repurchases, and refinance other indebtedness—all typical uses of debt issuance proceeds. This is a material creation of direct financial obligation under Item 2.03.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-22
EX-99.1
NOVONIX is applying for quotation of 129,334,163 ordinary fully paid shares issued on 22 June 2026 at AUD 0.16 per share as part of a placement previously announced in an Appendix 3B dated 17 June 2026. This represents a significant equity issuance that dilutes existing shareholders and raises approximately AUD 20.7 million in cash consideration, materially affecting the capital structure and ownership percentages of existing investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 90%
filed 2026-06-22
EX-99.2
NOVONIX announced a Share Purchase Plan (SPP) offering eligible shareholders the opportunity to purchase up to A$30,000 of new fully paid ordinary shares at A$0.16 per share (a 33.3% discount to market), targeting to raise approximately A$3.0 million. This SPP follows a concurrent institutional placement that raised approximately A$20.7 million, together constituting a material dilutive equity issuance of approximately A$23.7 million.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-06-22
Item 1.01
CRH entered into a definitive Agreement and Plan of Merger on June 21, 2026, to acquire Arcosa, Inc. for $150 per share in an all-cash transaction valued at approximately $8.5 billion. The transaction includes a $5.75 billion committed bridge facility and is expected to close in Q1 2027, subject to regulatory and stockholder approvals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
EyePoint held its Annual Meeting on April 21, 2026, with stockholders voting on four proposals: election of eight directors (all passed with substantial majorities), amendment to the 2023 Long-Term Incentive Plan to increase authorized shares by 4,900,000 (approved), non-binding advisory vote on named executive officer compensation (approved), and ratification of Deloitte & Touche LLP as independent auditor (approved with 99.4% support).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-22
Item 8.01
MapLight disclosed topline results from the Phase 2 IRIS trial of ML-004 in autism spectrum disorder on June 22, 2026. The trial did not meet its primary endpoint for social communication deficits but showed clinically meaningful improvement in irritability in adolescents with moderate-to-severe baseline irritability, with effect sizes comparable to approved antipsychotics.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-22
Item 8.01
TScan announced positive initial data from Cohort C of its Phase 1 ALLOHA™ study evaluating TSC-101, including manufacturing success rates, patient enrollment, chimerism outcomes, and safety results, with confirmation that the company remains on track to initiate a Phase 3 pivotal study. This represents a material clinical development milestone for the company's lead product candidate.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-06-22
Item 1.01
Ligand entered into a Fourth Amendment to its Credit Agreement on June 22, 2026, to permit the issuance of $550 million of convertible senior notes due 2031 in a private placement to qualified institutional buyers, with an additional $82.5 million option. The amendment accommodates this material debt issuance and affects the company's capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-22
Item 7.01
The filing discloses that Clearwater Analytics has obtained all required regulatory approvals (including FIRB approval from the Australian Treasurer on June 19, 2026) for its previously announced merger with GT Silver BidCo, Inc., with closing expected in Q2 2026. This represents a material milestone in the completion of a merger transaction that constitutes a change of control, making it a reportable M&A activity event under Item 1.01/2.01 framework, disclosed here under Item 7.01.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-22
EX-99.1
Brazil Potash announced the award of a second FEED (Front-End Engineering Design) contract to WSP UK Ltd. and Redpath Deilmann for mine shafts and underground development at the Autazes Project. This completes full-project FEED coverage and is material because it represents a critical milestone toward construction debt financing with Development Finance Institutions and Export Credit Agencies. The contract value is estimated at USD 26 million (with USD 4.3 million awarded for the initial Early Works phase), and the disclosure emphasizes that shaft sinking constitutes the critical path defining the entire project construction schedule. This is a material operational/strategic milestone for the development project, not a discrete event fitting other categories.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 8.01
Strategy Inc conducted an at-the-market (ATM) offering program, selling 2,714,839 shares of MSTR Stock and generating $335.5 million in net proceeds during the period, with a $21.0 billion MSTR Increase announced on March 23, 2026. ATM offerings are dilutive equity issuances that materially affect existing shareholders and represent significant capital-raising activity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Dr. Steve Kelsey, President of Research and Development, informed the Company of his intent to retire from employment effective January 4, 2027, with a transition to senior advisor role beginning July 1, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-22
Item 5.07
Revolution Medicines held its annual stockholder meeting on June 18, 2026, with shareholders voting on the election of two Class III directors (Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-22
Item 7.01
Taysha announced completion of dosing in the REVEAL pivotal trial for TSHA-102 and reported positive longer-term clinical data from Part A, including 100% of patients gaining/regaining developmental milestones and 310 total functional gains at ≥12 months post-treatment, representing a material clinical and regulatory milestone advancing toward BLA submission in 1H 2027.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Virgin Galactic is issuing shares of common stock and pre-funded warrants in exchange for approximately $52.5 million in principal amount of convertible notes. This is an unregistered equity issuance relying on Section 4(a)(2) of the Securities Act, issued to qualified institutional buyers and accredited investors. The transaction is material as it reduces debt by 75% while diluting existing shareholders through the issuance of new equity securities, and the company explicitly states the purpose is to "improve liquidity, manage its cash position and strengthen its balance sheet" ahead of commercial operations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-22
Item 7.01
The Board of Directors approved the separation and spin-off of Midera Food Processing, Inc. from Middleby Corporation into a new publicly traded company, with a pro rata distribution of Midera shares to Middleby stockholders scheduled for July 6, 2026. This constitutes a material change of control and disposition event—a significant restructuring that separates a major business unit and fundamentally alters the corporate structure. The filing explicitly references the Separation and Distribution Agreement and Form 10 registration statement, confirming this is a formal M&A-type transaction material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-22
Item 8.01
This Item 8.01 disclosure announces the completion of a material spin-off transaction—the separation of Middleby's Food Processing business into an independent, publicly traded company (Midera Food Processing, Inc.). The filing describes the distribution of 100% of SpinCo common stock to Middleby stockholders on a pro rata basis, with a distribution date of July 6, 2026, and Nasdaq listing under ticker "MFP." This constitutes a material change of control and restructuring of the registrant's ownership and capital structure, fitting the definition of ma_activity (change of control and separation transaction).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-22
Item 5.02
The disclosure centers on a new employment agreement with CEO Ramesh Srinivasan that establishes compensatory arrangements: a $600,000 base salary, annual bonus eligibility up to 150% of base salary, and a substantial $6.8 million RSU grant (78,269 units) with both time-based and performance-based vesting conditions tied to stock price targets ($105–$135 per share). The agreement also specifies severance and change-of-control provisions. This is a material executive compensation arrangement under Item 5.02(e).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-22
EX-99.1
This press release announces FDA accelerated approval of Tzield (teplizumab-mzwv) for a new indication—delaying decline in endogenous insulin production in children aged 8–17 with recently diagnosed stage 3 type 1 diabetes. The approval is a significant regulatory and commercial milestone for Sanofi's pipeline, expanding the drug's approved indications and market opportunity. While not a discrete M&A, debt, or capital event, the regulatory approval of a first-in-class disease-modifying therapy for a new patient population is a material operational and strategic development that would affect a reasonable investor's assessment of the company's product portfolio and revenue prospects.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-06-22
Item 5.02
Laura Cockrill was appointed as Executive Vice President and Chief Financial Officer effective June 22, 2026, succeeding Axel André who will depart July 17, 2026. The appointment of a new CFO to this critical C-suite position is material to investors as it affects the company's financial leadership and governance structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-22
Item 3.02
Digital Realty announced three material acquisition transactions totaling approximately $1.61 billion: acquisition of approximately 1,440 acres of land in Kansas City for ~$475 million, increase in Teraco ownership from 61% to 77% through acquisition of a 16% stake for ~$650 million, and acquisition of Columbia Capital for ~$485 million. These transactions are funded principally through issuance of 6.3 million shares of common stock and are expected to enhance the company's growth profile.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-22
Item 7.01
Jaguar Health's Board has initiated a process to explore and review strategic alternatives "focused on maximizing stockholder value," explicitly including "mergers, reverse mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions." This disclosure of an active exploration process for potential M&A activity or change-of-control transactions is material to investors assessing the company's future direction and value, even though no specific transaction has been announced yet.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
EX-99.3
SOPHiA GENETICS completed a $57.5 million public offering of 12,104,900 ordinary shares at $4.75 per share, including 1,578,900 shares from full exercise of the underwriters' option. The offering was initially announced and priced at $50 million for 10,526,000 shares, with the underwriters' option fully exercised at closing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-06-22
Item 2.02
Ennis, Inc. issued a press release on June 22, 2026 announcing financial results for the quarter ended May 31, 2026, disclosing revenues of $98.6 million (up 1.4% YoY), net earnings of $9.9 million, and diluted EPS of $0.39 (up from $0.38), with gross profit margin improving to 31.5% from 31.1%.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
EQT Infrastructure Company LLC disclosed an unregistered sale of 6,381,666 equity shares across multiple classes for aggregate consideration of approximately $171.8 million as of June 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S. Since inception on February 1, 2026, the Company has sold approximately $711.5 million of such shares as part of a continuous private offering, representing a material capital raise affecting investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
EQT Private Equity Company LLC completed an unregistered sale of approximately $41.9 million in equity shares (1,449,986 shares across multiple classes) to third-party investors as of June 1, 2026, under Section 4(a)(2) and Regulations D and S. This private placement is part of a continuous offering that has raised approximately $788.3 million since inception.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting held on June 18, 2026, covering three matters: election of 11 directors, advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. The filing directly corresponds to Item 5.07 and presents the vote tallies for each proposal, making this a textbook shareholder_vote_results event that is material to investors assessing corporate governance and board composition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-06-22
Item 1.01
First Tracks entered into a 12-month sublease for approximately 45,057 square feet of office space in San Diego on June 15, 2026. While disclosed under Item 1.01 (Material Definitive Agreement), this is a real estate lease arrangement rather than an acquisition, disposition, merger, or change of control. The sublease is material to investors as it represents a significant operational commitment (45,000+ sq ft facility) and ongoing financial obligation, but it is fundamentally an operational/strategic business arrangement rather than a transaction fitting the M&A taxonomy. Classified as operational_other because the event is clearly operational (facility lease) but does not fit the specific M&A categories that Item 1.01 typically covers.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-22
Item 7.01
Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil), the company's lead product candidate for complicated urinary tract infections and the first-and-only oral carbapenem antibiotic approved in this indication. This represents a major regulatory milestone and transition from development to commercialization, materially affecting the company's commercial prospects and future revenue potential.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
PennantPark Private Income Fund issued 110,906 common shares for approximately $2.864 million in an unregistered private offering relying on Section 4(a)(2) and Regulation D exemptions, diluting existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-22
Item 5.02
Joseph H. Jordan was appointed Chief Executive Officer and director of Domino's Pizza, effective October 1, 2026, following a multi-year succession planning process. The appointment follows Russell J. Weiner's transition to Executive Chairman and David A. Brandon's retirement from the Board.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
Oric Pharmaceuticals held its annual meeting of stockholders on June 18, 2026, with voting results on five proposals: election of Class III directors (Jacob M. Chacko and Mardi C. Dier), ratification of KPMG LLP as independent auditor, approval of the amended 2020 Equity Incentive Plan, advisory approval of named executive officer compensation, and advisory vote on frequency of future compensation votes. All proposals passed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
BridgeBio held its Annual Meeting of Stockholders on June 16, 2026, at which shareholders voted on the election of two Class I directors (Peter Lebowitz and Frank P. McCormick) and the ratification of Deloitte & Touche LLP as independent auditor, with detailed vote tallies disclosed.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 96%
filed 2026-06-22
Item 2.03
Adaptive Biotechnologies issued $345 million in aggregate principal amount of 0% Convertible Senior Notes due 2031 on June 22, 2026, with conversion mechanics, redemption provisions, and specified use of proceeds including $156.9 million to repay the OrbiMed Purchase Agreement, $25.6 million for capped call costs, $25.0 million for share repurchases, and remainder for general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Adaptive Biotechnologies issued $300 million of convertible senior notes in a private placement to qualified institutional buyers under Rule 144A, with up to 20,034,840 shares of common stock potentially issuable upon conversion, representing a dilutive unregistered equity issuance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Dr. Ichiro Aoki, co-founder and President of indie Semiconductor, resigned from the Board and his President role effective June 29, 2026, transitioning to a limited technical advisor role. Thomas Schiller was concurrently appointed to the Board as part of the leadership transition.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-06-22
EX-99.1
Legend Biotech announced the pricing of a public offering of 7.7 million ADSs at $29.35 per share, generating approximately $226 million in gross proceeds. This is a material equity issuance that creates a direct financial obligation and dilutes existing shareholders. While technically an equity offering rather than debt, the taxonomy's `debt_issuance` category encompasses "creation of a new direct financial obligation" and is the closest fit for capital-raising activities that materially affect the registrant's financial structure and shareholder base.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing reports voting outcomes for three proposals: election of Class III directors (Proposal 1), ratification of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of named executive officer compensation (Proposal 3), with detailed vote tallies for each. This is a standard Item 5.07 disclosure and is material as it reflects stockholder approval of governance and compensation matters.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-22
Item 2.01
Ridgepost Capital, Inc. completed its acquisition of Stellus Capital Management, LLC on June 22, 2026, for $125 million in cash, 11.2 million membership units, and 579,096 shares of Class A Common Stock, plus up to $60 million in earnout payments. The acquisition of a $4 billion AUM direct lending platform represents a significant strategic transaction for the registrant.
View raw filing on EDGAR →